
Quarterly ResultNov 3, 2026, 08:22 AM
Revvity Q3 Revenue $729M, Adj. EPS $1.38; Raises FY26 Guidance
AI Summary
Revvity, Inc. announced its third quarter financial results, reporting revenue of $729 million, a 4.4% increase year-over-year. GAAP EPS from continuing operations rose to $0.56 from $0.41, and adjusted EPS from continuing operations increased to $1.38 from $1.18. The company also provided pro forma results, showing revenue of $710 million and pro forma adjusted EPS of $1.37. Revvity raised its full-year 2026 guidance and announced an upcoming Investor Day on November 13, 2026. The company also furnished pro forma financial statements reflecting the probable sale of its China Immunodiagnostics business.
Key Highlights
- Revvity reported Q3 revenue of $729 million, a 4.4% increase year-over-year.
- GAAP EPS from continuing operations was $0.56, up from $0.41 in the prior year.
- Adjusted EPS from continuing operations was $1.38, an increase from $1.18 year-over-year.
- Pro forma revenue for Q3 was $710 million, with pro forma organic revenue growth of 7%.
- Pro forma adjusted EPS from continuing operations was $1.37, up from $1.13 in the prior year.
- The company raised its full-year 2026 guidance.
- Revvity plans to host an Investor Day on November 13, 2026.
Price Impact
More from RVTY